Supplementary Materials

The following analyses of the single-dose and two-dose methotrexate subgroups are provided as supplementary material.

The methotrexate group was divided into two subgroups: single-dose methotrexate (n = 24) and two-dose methotrexate (n = 14). The demographic and obstetric characteristics of the two groups are presented in Supplementary Table 1. No statistically significant differences were identified between the groups in terms of age, height, weight, body mass index, gravida, parity, vaginal delivery, cesarean section, and number of abortions.

The laboratory and sonographic characteristics of the single-dose and two-dose methotrexate groups are presented in Supplementary Table 2. No statistically significant differences were found between the groups in terms of baseline and fourth-month anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) levels and their changes, baseline and follow-up endometrial measurements, and endometrial thickness changes.

The comparison of pre-treatment and post-treatment findings in the single-dose methotrexate group is presented in Supplementary Table 3. While no significant differences were observed in AMH levels between the pre-treatment and post-treatment periods, statistically significant differences were observed in FSH levels and endometrial thickness.

The comparison of pre-treatment and post-treatment findings in the two-dose methotrexate group is presented in Supplementary Table 4. No significant differences were observed in AMH levels and endometrial thickness between pre-treatment and post-treatment periods; however, a statistically significant difference was identified in FSH levels.

Supplementary Table 1. Demographic and obstetric characteristics of the single-dose and two-dose methotrexate.

	Single-dose methotrexate (n = 24)	Two-dose methotrexate (n = 14)	p
Age (year)	30.42 ± 5.4	30.4 ± 5.3	0.974
Height (cm)	162.2 ± 4.64	161.1 ± 4.64	0.521
Weight (kg)	66 (57-96)	68.5 (51-105)	0.988
BMI (kg/m^2)	26.08 ± 3.52	26.96 ± 4.78	0.518
Gravida (n)	3 (1-5)	3 (1-7)	0.687
Parity (n)	1 (0-3)	1 (0-6)	0.917
Number of vaginal births (n)	0.5 (0-3)	0 (0-4)	0.501
Number of cesarean sections (n)	0 (0-2)	0 (0-3)	0.520
Number of abortions (n)	0 (0-3)	0 (0-2)	0.893

BMI, body mass index.

Supplementary Table 2. Laboratory and sonographic characteristics of the single-dose and two-dose methotrexate.

	Single-dose methotrexate (n = 24)	Two-dose methotrexate (n = 14)	p
β-hCG	841 (66-6268)	1933.5 (195-13100)	0.273
Baseline AMH	1.51 (0.17-6.46)	2.12 (1.1-5.45)	0.106
4th month AMH	1.41 (0.18-6.84)	2.65 (1.21-5.32)	0.071
AMH change	0.06 (-0.52-1.28)	0.08 (-0.63-1.34)	0.377
Baseline FSH	2.59 (0.11-10.95)	1.48 (0.15-5.21)	0.315
4th month FSH	5.56 ± 1.86	6.34 ± 2.27	0.257
FSH change	3.02 (-6.77-7.50)	4.88 (-2.91-9.23)	0.100
Baseline endometrial thickness (mm)	8 (4-25)	6.5 (4-18)	0.247
Control endometrial thickness (mm)	5.5 (3-11)	5 (3-10)	0.161
Endometrial thickness change	-2.5 (-15-3)	-1.5 (-12-4)	0.622
Presence of adnexal mass (n, %)	21 (87.5%)	11 (78.6%)	0.650
Size of adnexal mass (mm)	23 (7-70)	20 (7-40)	0.611
Presence of free fluid (n, %)	10 (41.7%)	6 (42.9%)	1.000

β-hCG, beta human chorionic gonadotropin; AMH, anti-Müllerian hormone; FSH, follicle-stimulating hormone.

Supplementary Table 3. Comparison of pre-treatment and post-treatment findings in the single-dose methotrexate group.

	Pre-treatment	Post-treatment	p
AMH (ng/mL)	1.51 (0.17-6.46)	1.41 (0.18-6.84)	0.875
FSH (mIU/mL)	2.59 (0.11-10.95)	4.89 (3-9.32)	**0.001**
Endometrial thickness (mm)	8 (4-25)	5.5 (3-11)	**0.001**

Wilcoxon signed-rank test. AMH, anti-Müllerian hormone; FSH, follicle-stimulating hormone.

Supplementary Table 4. Comparison of pre-treatment and post-treatment findings in the two-dose methotrexate.

	Pre-treatment	Post-treatment	p
AMH (ng/mL)	2.12 (1.1-5.45)	2.65 (1.21-5.32)	0.315
FSH (mIU/mL)	1.48 (0.15-5.21)	6.99 (2.3-9.81)	**0.002**
Endometrial thickness (mm)	6.5 (4-18)	5 (3-10)	0.050

Wilcoxon signed-rank test. AMH, anti-Müllerian hormone; FSH, follicle-stimulating hormone.